Yusimry
Adalimumab biosimilar developed by Coherus BioSciences, development code CHS-1420. Reference product Humira.
Brands by market: Yusimry (USA) · Commercial partner or holder: Emerge Bioscience (current US applicant)
FDADec 2021approved
EMAnot listed
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States · Yusimry
US Food and Drug AdministrationApprovedBrand
Yusimry
Holder or applicant
Emerge Bioscience Pte. Ltd.
Pathway
351(k)
Approved
Dec 2021
Application or permission
761216
Licence type
351(k) biosimilar, not interchangeable
Presentations
40/0.8
Source
S001, S016
EMA
European Union
Not listed by EMA.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- FDADec 2021Approved by FDA
Sources
S001FDA, Biosimilar Product Information (approved biosimilars table) Primary (regulator)S016FDA Purple Book, monthly data downloads January to August 2026 Primary (regulator)
Planning adalimumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.